The thorniest questions facing pharma, according to a leading bioethicist
PharmaVoice
NOVEMBER 6, 2023
Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.
Bioethics Related Topics 
246 
STAT+: Venture capitalists want to own hospitals. Can they do better than private equity?
STAT
NOVEMBER 1, 2023
Given workforce shortages, clinician burnout, rising drug costs, and a surging aging population, “it’s not that big a leap to say that more such purchases are going to occur,” said Robert Klitzman, a Columbia psychiatry professor and director of its bioethics masters program.
Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Bioethics International reveals index to score pharma on trial diversity
Outsourcing Pharma
JANUARY 12, 2023
The not-for-profit organization published its fair inclusion score to measure and rank pharmaceutical companies on their inclusion of women, older adults, and racial and ethnic minoritized patients.
STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug
STAT
MARCH 6, 2023
”It’s imprudent and unwise and not the way forward, even for people who are very ill,” said Dr. Arthur Caplan, a professor of bioethics at the NYU Langone hospital system in New York who chaired a university panel that studied the FDA’s compassionate use program.
Bayer Pharmaceuticals accelerates innovations for patients
LifeProNow
MARCH 27, 2023
Bayer works on leveraging all the possibilities of the technologies while fully integrating all regulatory and bioethical requirements.” ” [link] The post Bayer Pharmaceuticals accelerates innovations for patients appeared first on LifeProNow.
Study shows there is still a long way to go on trial diversity
pharmaphorum
JANUARY 5, 2023
Bioethics International has developed a benchmarking tool for “fair inclusion” in clinical trials, drawing on pivotal trials submitted to the FDA in support of 59 new cancer therapeutics – submitted by 25 sponsors – that were approved by the regulator between 2012 and 2017.
NHC Comments on Notice of Proposed Rulemaking on Discrimination on the Basis of Disability in Health and Human Service Programs or Activities
Putting Patients First Blog
NOVEMBER 14, 2023
Medical futility and disability bias: part of the bioethics and disability series. Retrieved from https ://w ww.cdc.gov/ncbd d d/disabilityandhealth/infographic-disability-impacts-all.html 14 National Council on Disability. National Council on Disability. link] 15 FitzGerald, C. and Hurst, S.
Let's personalize your content